# A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma

Source: https://onco.cc/trials/nct07582432/  
OnCo record `nct07582432` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Gamunex-C, 10% Injectable Solution in non-Hodgkin lymphoma, run by Grifols Biologicals, LLC, now recruiting.

## Summary

A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma is a phase 3 interventional study registered as NCT07582432 by Grifols Biologicals, LLC, with 49 participants planned, started 2026-04-23 and due to reach its primary completion in 2028-08-31. Interventions recorded: Gamunex-C, 10% Injectable Solution.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07582432
- Phase: 3
- Setting: An Open-label, Multi-Center, Single-arm Prospective Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex®-C Plus Standard Medical Treatment to Prevent Infections in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
- Sponsor: Grifols Biologicals, LLC
- Enrolled: 49

## Sources

- ClinicalTrials.gov NCT07582432: https://clinicaltrials.gov/study/NCT07582432

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- companies: [Grifols](https://onco.cc/companies/grifols/)

---
JSON: https://onco.cc/api/v1/entities/nct07582432.json